Objective:To observe the effects of edaravone combined with urinary kallidinogenase on serum ox-LDL, PCT, hs-CRP, TNF-α and T cell subsets in patients with acute cerebral infarction, so as to explore the mechanisms o...Objective:To observe the effects of edaravone combined with urinary kallidinogenase on serum ox-LDL, PCT, hs-CRP, TNF-α and T cell subsets in patients with acute cerebral infarction, so as to explore the mechanisms of combination therapy on patients with acute cerebral infarction. Methods:86 cases of patients with acute cerebral infarction in our hospital from March 2014 to May 2016 were randomly divided into two groups:control group and observation group, 43 cases in each group. All patients were given general treatment according to their own specific conditions, including hypoglycemic, pressure adjustment, prevention and treatment of complications, symptomatic support therapy, etc. The control group were given 30 mg Edaravone Injection on this basis with once per day for 14 d;The observation group was treated with 0. 15 PNA urinary kallidinogenase intravenous drip with once per day for 14 d on the basis of the control group. The levels of serum x-LDL, PCT, hs-CRP, TNF-αand CD3+, CD4+, CD8+, CD4+/CD8+were detected and compared between the two groups. Results:(1) Before treatment, there was no significant difference between the two groups on the levels of serum ox-LDL, PCT, hs-CRP, and TNF-α;after treatment, the serum levels of ox-LDL, PCT, hs-CRP and TNF-αin the two groups were significantly lower than that before treatment, and the difference was significant (P<0.05);(2) Before treatment, there was no significant difference between the two groups on the levels of serum CD3+, CD4+, CD8+, CD4+/CD8+;after treatment, the serum levels of CD3+, CD4+and CD4+/CD8+were significantly increased in the two groups, and the level of CD8+was significantly decreased compared with the same group before treatment, and the difference was significant (P<0.05);and the levels of serum CD3+, CD4+, CD8+and CD4+/CD8+in the observation group were significantly better than those in the control group, and the difference was significant (P<0.05). Conclusions:The treatment of combined application of urinary kallidinogenase and edaravone in patients with acute cerebral infarction, can significantly improve the serum levels of ox-LDL, PCT, hs-CRP, TNF-αand T cell subsets, further illustrates the synergistic effect of the combination, also shows that the two drugs for acute cerebral infarction can inhibit thrombosis to expand, reduce inflammation, relieve cerebral tissue damage, and improve neurological function.展开更多
文摘Objective:To observe the effects of edaravone combined with urinary kallidinogenase on serum ox-LDL, PCT, hs-CRP, TNF-α and T cell subsets in patients with acute cerebral infarction, so as to explore the mechanisms of combination therapy on patients with acute cerebral infarction. Methods:86 cases of patients with acute cerebral infarction in our hospital from March 2014 to May 2016 were randomly divided into two groups:control group and observation group, 43 cases in each group. All patients were given general treatment according to their own specific conditions, including hypoglycemic, pressure adjustment, prevention and treatment of complications, symptomatic support therapy, etc. The control group were given 30 mg Edaravone Injection on this basis with once per day for 14 d;The observation group was treated with 0. 15 PNA urinary kallidinogenase intravenous drip with once per day for 14 d on the basis of the control group. The levels of serum x-LDL, PCT, hs-CRP, TNF-αand CD3+, CD4+, CD8+, CD4+/CD8+were detected and compared between the two groups. Results:(1) Before treatment, there was no significant difference between the two groups on the levels of serum ox-LDL, PCT, hs-CRP, and TNF-α;after treatment, the serum levels of ox-LDL, PCT, hs-CRP and TNF-αin the two groups were significantly lower than that before treatment, and the difference was significant (P<0.05);(2) Before treatment, there was no significant difference between the two groups on the levels of serum CD3+, CD4+, CD8+, CD4+/CD8+;after treatment, the serum levels of CD3+, CD4+and CD4+/CD8+were significantly increased in the two groups, and the level of CD8+was significantly decreased compared with the same group before treatment, and the difference was significant (P<0.05);and the levels of serum CD3+, CD4+, CD8+and CD4+/CD8+in the observation group were significantly better than those in the control group, and the difference was significant (P<0.05). Conclusions:The treatment of combined application of urinary kallidinogenase and edaravone in patients with acute cerebral infarction, can significantly improve the serum levels of ox-LDL, PCT, hs-CRP, TNF-αand T cell subsets, further illustrates the synergistic effect of the combination, also shows that the two drugs for acute cerebral infarction can inhibit thrombosis to expand, reduce inflammation, relieve cerebral tissue damage, and improve neurological function.
